NovoCure Limited Operating Cash Flow
NovoCure Limited (NVCR) reported Operating Cash Flow of $8.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-07-23
- NovoCure Limited net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $8.13M.
- NovoCure Limited net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$13.52M.
- NovoCure Limited net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$18.00M.
- NovoCure Limited net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $20.57M, a 98.28% increase year-over-year.
- NovoCure Limited net cash provided by (used in) operating activities for fiscal 2024 was -$26.37M.
- NovoCure Limited net cash provided by (used in) operating activities for fiscal 2023 was -$73.34M, a 338.20% decline from fiscal 2022.
- NovoCure Limited net cash provided by (used in) operating activities for fiscal 2022 was $30.79M, a 62.80% decline from fiscal 2021.
- NovoCure Limited net cash provided by (used in) operating activities for fiscal 2021 was $82.76M, a 16.53% decline from fiscal 2020.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.13M 10-Q · filed 2026-07-23 | -$5.38M 10-Q · filed 2026-07-23 | -$23.39M derived: sum of 3 quarters · filed 2026-07-23 | -$2.81M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | -$13.52M 10-Q · filed 2026-04-30 | -$31.52M derived: sum of 2 quarters · filed 2026-07-23 | -$10.95M derived: sum of 3 quarters · filed 2026-07-23 | -$26.88M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | -$18.00M derived: 10-Q 12 month − 10-Q 9 month · filed 2026-07-23 | $2.57M derived: sum of 2 quarters · filed 2026-07-23 | -$13.37M derived: sum of 3 quarters · filed 2026-07-23 | -$49.03M 10-Q · filed 2026-07-23 |
| 2025-09-30 | $20.57M 10-Q · filed 2025-10-30 | $4.64M derived: sum of 2 quarters · filed 2026-07-23 | -$31.03M 10-Q · filed 2025-10-30 | -$34.48M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | -$15.94M 10-Q · filed 2026-07-23 | -$51.60M 10-Q · filed 2026-07-23 | -$55.05M derived: sum of 3 quarters · filed 2026-07-23 | -$44.68M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | -$35.66M 10-Q · filed 2026-04-30 | -$39.12M derived: sum of 2 quarters · filed 2026-04-30 | -$28.74M derived: sum of 3 quarters · filed 2026-04-30 | -$30.46M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$3.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.92M derived: sum of 2 quarters · filed 2026-02-26 | $5.21M derived: sum of 3 quarters · filed 2026-02-26 | -$26.37M 10-K · filed 2026-02-26 |
| 2024-09-30 | $10.38M 10-Q · filed 2025-10-30 | $8.66M derived: sum of 2 quarters · filed 2025-10-30 | -$22.92M 10-Q · filed 2025-10-30 | -$37.48M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$1.72M 10-Q · filed 2025-07-24 | -$33.29M 10-Q · filed 2025-07-24 | -$47.85M derived: sum of 3 quarters · filed 2026-02-26 | -$67.17M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$31.57M 10-Q · filed 2025-04-24 | -$46.13M derived: sum of 2 quarters · filed 2026-02-26 | -$65.45M derived: sum of 3 quarters · filed 2026-02-26 | -$88.18M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$14.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$33.87M derived: sum of 2 quarters · filed 2026-02-26 | -$56.61M derived: sum of 3 quarters · filed 2026-02-26 | -$73.34M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$19.31M 10-Q · filed 2024-10-30 | -$42.05M derived: sum of 2 quarters · filed 2024-10-30 | -$58.78M 10-Q · filed 2024-10-30 | -$62.48M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$22.74M 10-Q · filed 2024-07-25 | -$39.46M 10-Q · filed 2024-07-25 | -$43.17M derived: sum of 3 quarters · filed 2025-02-27 | -$20.75M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$16.73M 10-Q · filed 2024-05-02 | -$20.43M derived: sum of 2 quarters · filed 2025-02-27 | $1.99M derived: sum of 3 quarters · filed 2025-02-27 | $17.75M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$3.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $18.71M derived: sum of 2 quarters · filed 2025-02-27 | $34.48M derived: sum of 3 quarters · filed 2025-02-27 | $30.79M 10-K · filed 2025-02-27 |
| 2022-09-30 | $22.42M 10-Q · filed 2023-10-26 | $38.18M derived: sum of 2 quarters · filed 2023-10-26 | $34.49M 10-Q · filed 2023-10-26 | $48.90M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $15.76M 10-Q · filed 2023-07-27 | $12.07M 10-Q · filed 2023-07-27 | $26.48M derived: sum of 3 quarters · filed 2024-02-22 | $50.88M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$3.69M 10-Q · filed 2023-05-04 | $10.72M derived: sum of 2 quarters · filed 2024-02-22 | $35.12M derived: sum of 3 quarters · filed 2024-02-22 | $61.29M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $14.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $38.80M derived: sum of 2 quarters · filed 2024-02-22 | $64.98M derived: sum of 3 quarters · filed 2024-02-22 | $82.76M 10-K · filed 2024-02-22 |
| 2021-09-30 | $24.40M 10-Q · filed 2022-10-27 | $50.57M derived: sum of 2 quarters · filed 2022-10-27 | $68.35M 10-Q · filed 2022-10-27 | $121.83M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $26.17M 10-Q · filed 2022-07-28 | $43.95M 10-Q · filed 2022-07-28 | $97.43M derived: sum of 3 quarters · filed 2023-02-23 | $128.40M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $17.78M 10-Q · filed 2022-04-28 | $71.26M derived: sum of 2 quarters · filed 2023-02-23 | $102.23M derived: sum of 3 quarters · filed 2023-02-23 | $114.97M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $53.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $84.45M derived: sum of 2 quarters · filed 2023-02-23 | $97.19M derived: sum of 3 quarters · filed 2023-02-23 | $99.15M 10-K · filed 2023-02-23 |
| 2020-09-30 | $30.97M 10-Q · filed 2021-10-28 | $43.71M derived: sum of 2 quarters · filed 2021-10-28 | $45.67M 10-Q · filed 2021-10-28 | $52.63M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $12.74M 10-Q · filed 2021-07-29 | $14.70M 10-Q · filed 2021-07-29 | $21.66M derived: sum of 3 quarters · filed 2022-02-24 | $36.57M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $1.96M 10-Q · filed 2021-04-29 | $8.92M derived: sum of 2 quarters · filed 2022-02-24 | $23.83M derived: sum of 3 quarters · filed 2022-02-24 | $32.89M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $6.96M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $21.87M derived: sum of 2 quarters · filed 2022-02-24 | $30.93M derived: sum of 3 quarters · filed 2022-02-24 | $26.62M 10-K · filed 2022-02-24 |
| 2019-09-30 | $14.91M 10-Q · filed 2020-10-29 | $23.97M derived: sum of 2 quarters · filed 2020-10-29 | $19.66M 10-Q · filed 2020-10-29 | $36.47M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $9.07M 10-Q/A · filed 2020-10-02 | $4.75M 10-Q/A · filed 2020-10-02 | $21.57M derived: sum of 3 quarters · filed 2021-02-25 | $27.20M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$4.32M 10-Q/A · filed 2020-10-02 | $12.50M derived: sum of 2 quarters · filed 2021-02-25 | $18.14M derived: sum of 3 quarters · filed 2021-02-25 | $10.64M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $16.81M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $22.45M derived: sum of 2 quarters · filed 2021-02-25 | $14.96M derived: sum of 3 quarters · filed 2021-02-25 | -$1.86M 10-K · filed 2021-02-25 |
| 2018-09-30 | $5.64M 10-Q · filed 2019-10-31 | -$1.85M derived: sum of 2 quarters · filed 2019-10-31 | -$18.68M 10-Q · filed 2019-10-31 | -$21.58M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | -$7.49M 10-Q · filed 2019-07-25 | -$24.32M 10-Q · filed 2019-07-25 | -$27.21M derived: sum of 3 quarters · filed 2020-02-27 | -$24.67M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | -$16.82M 10-Q · filed 2019-05-02 | -$19.72M derived: sum of 2 quarters · filed 2020-02-27 | -$17.18M derived: sum of 3 quarters · filed 2020-02-27 | -$23.05M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | -$2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$351.00K derived: sum of 2 quarters · filed 2020-02-27 | -$6.23M derived: sum of 3 quarters · filed 2020-02-27 | -$33.13M 10-K · filed 2020-02-27 |
| 2017-09-30 | $2.55M 10-Q · filed 2018-10-25 | -$3.33M derived: sum of 2 quarters · filed 2018-10-25 | -$30.24M 10-Q · filed 2018-10-25 | |
| 2017-06-30 | -$5.88M 10-Q · filed 2018-07-26 | -$32.78M 10-Q · filed 2018-07-26 | ||
| 2016-12-31 | -$107.59M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEMAITRE VASCULAR INC (LMAT) | United States | $1.848B | 33.37 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |